Seminar on drug patent link and patent period compensation system held in Yantai

Source: China Association for the promotion of pharmaceutical innovation June 9, 2017, China Association for the promotion of pharmaceutical innovation (hereinafter referred to as "China Association for the promotion of pharmaceutical") held a seminar on "pharmaceutical patent link and patent period compensation system" in Yantai Relevant leaders of State Food and drug administration, State Intellectual Property Office, science and Education Department of health and Family Planning Commission and other departments attended the meeting Representatives from more than 30 member units and experts from the professional committee of the China Council for the promotion of drugs, nearly 70 people attended the seminar The meeting discussed the feasibility of introducing drug patent link system and patent period compensation system in China and how to implement them Song Ruilin, executive chairman of China Association for the promotion of drugs, made a detailed introduction to the background, controversy and implementation effect of the above patent system in European and American countries He pointed out that the international practice has proved that the complete and operable patent link system and patent period compensation system provide market predictability for all market participants, and the establishment of patent link system can not be simply considered as a single issue In terms of patent protection, this system also promotes the development of generic drugs, which encourages the industry to continue to develop towards innovation and provides system guarantee for high-quality generic drugs and morning market At the same time, he pointed out that blindly copying foreign patent protection system will inevitably affect the development of the industry Is the establishment of patent link and patent compensation period system in China harmful to the development of China's pharmaceutical industry or promoting the development of China's pharmaceutical industry? Will the establishment of the above system affect the accessibility of drugs? It is the focus of this symposium Member representatives and experts at the meeting made in-depth discussions on whether the reform of drug patent system will restrict the development of domestic generic drugs It is agreed that the introduction of drug patent link and patent period compensation system to fully protect the research and development results of new drugs will not only encourage the R & D personnel to dare to innovate continuously, but also encourage enterprises to challenge patents and launch the first generic drugs as soon as possible, which will surely have important significance for accelerating the innovation and development of China's pharmaceutical industry However, the design of China's pharmaceutical patent link and patent period compensation system should both encourage the innovation of China's pharmaceutical industry and promote the coordinated development of imitation In order to better support the balanced development of innovation and imitation of China's pharmaceutical industry, many opinions and suggestions are put forward around how to establish China's pharmaceutical patent link and patent period compensation system Wang Lifeng, director of the drug and cosmetic registration department of the State Food and Drug Administration (CFDA), pointed out that the implementation of a series of reform measures of drug supervision has achieved good results, but with the deepening of the reform, it also exposed the deep-seated problems of China's lack of a complete policy and legal system to encourage drug innovation, which needs to be studied from a global perspective to promote the overall development of China's pharmaceutical industry To benefit the people and improve public health President Song Ruilin said that at present, China Council for the promotion of drugs, entrusted by CFDA, is carrying out research on the necessity and feasibility of China's introduction of drug patent link and patent period compensation system, and has conducted in-depth research on the relevant systems of international mainstream countries; we will listen to industrial opinions carefully, and keep in touch with relevant national departments at any time, so as to formulate favorable policies for CFDA to promote Chinese medicine The scientific system of pharmaceutical patent that can optimize and upgrade the pharmaceutical industry, guide the innovation and development of enterprises and guarantee the public health can provide reference Workshop site 1 workshop site 2